Vincerx Pharma Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Vincerx Pharma Stock Summary

Vincerx Pharma competes with Spero Therapeutics, Bolt Biotherapeutics, Coherus BioSciences, Applied Therapeutics, and Lyra Therapeutics. Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California. Vincera Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people.

Vincerx Pharma Key Financial Ratios

Vincerx Pharma Key Balance Sheet Accounts

Vincerx Pharma Key Income Statement Accounts

Vincerx Pharma Key Cash Accounts

Vincerx Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Vincerx Pharma's current stock value. Our valuation model uses many indicators to compare Vincerx Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vincerx Pharma competition to find correlations between indicators driving Vincerx Pharma's intrinsic value. More Info.Vincerx Pharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Vincerx Pharma's Return On Equity is projected to drop slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vincerx Pharma's earnings, one of the primary drivers of an investment's value.

Vincerx Pharma Systematic Risk

Today, most investors in Vincerx Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vincerx Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Vincerx Pharma growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Vincerx Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Vincerx Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Vincerx Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Vincerx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vincerx Pharma's daily price indicators and compare them against related drivers.

When running Vincerx Pharma's price analysis, check to measure Vincerx Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vincerx Pharma is operating at the current time. Most of Vincerx Pharma's value examination focuses on studying past and present price action to predict the probability of Vincerx Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vincerx Pharma's price. Additionally, you may evaluate how the addition of Vincerx Pharma to your portfolios can decrease your overall portfolio volatility.